D
iscovering useful drugs to treat tuberculosis is not an exercise for the faint of heart. Screening for agents that inhibit the growth of the causative myco bacterium produces very few hits, and optimizing those hits into drug-like 'lead' molecules is exceptionally difficult, owing to the bacterium's impermeable cell envelope. Even armed with a promising lead, animal models and early-stage clinical trials have little predictive value, and the long duration of therapy currently required to treat tuberculosis makes safety hurdles much higher than for most bacterial infections. So, an attractive strategy, and one that lies at the heart of a report by Lee et al. 1 in Nature Medicine, is to repurpose an existing antibiotic class that is already known to be safe and effective in other infections, but that has poor antitubercular activity.
The authors focused their efforts on spectino mycin, a natural product isolated from Streptomyces bacteria that has a long history of safe use for the treatment of gonorrhoea in patients who are allergic (or resistant) to penicillin. Despite targeting the bacterial ribosome -a complex of proteins and RNA molecules that is essential for cellular protein translation and that is highly evolutionarily conserved -spectinomycin shows little activity against Mycobacterium tuberculosis. Other translation inhibitors, such as streptomycin, kanamycin and amikacin, are widely used in antituberculosis chemotherapy, but their binding site on the ribosome is distinct from that of spectinomycin.
Armed with the crystal structure of spectinomycin bound to the bacterial ribosome 2 and a mutant strain of M. tuberculosis defective in a cellular efflux pump that showed increased susceptibility to spectinomycin, Lee and colleagues produced derivatives of the antibiotic, called spectinamides, that showed potent antituberculosis activity both in vitro and in mice. The co-crystal structure of the drug bound to the bacterial ribosome allowed the authors to deduce which sites in the drug were crucial for binding and which were not; they then focused on the latter, chemically modifying the natural product to improve cellular activity by reducing drug efflux. They assessed the effect of the modifications on efflux by comparing the activity of the compounds in wild-type and efflux-mutant bacteria, and used separate in vitro assays to monitor the modified products' ribosome-binding ability.
Drug developers have long had a love-hate relationship with natural products. On the one hand, the sheer complexity and threedimensionality of natural products provides more opportunity for highly specific, tight binding to potential targets than do the small, flat synthetic molecules that are typical of the large libraries amassed by most pharmaceutical companies (Fig. 1) . Many natural products have evolved as weapons deployed by bacteria to kill other bacteria, and taking advantage of that evolutionary war has obvious attractions. On the other hand, natural compounds rarely have the ideal pharmacological properties needed for direct use, and therefore require chemical transformation -a process called semisynthesis -to make them suitable as medicines. Such semisyntheses can be extra ordinarily complex and require enormous investment to understand the chemical properties of the parent molecule, thereby allowing a systematic exploration of where alterations can be made.
Current practice among scientists working in tuberculosis drug discovery is heavily weighted towards screening and optimizing small synthetic lead molecules. One such molecule, bedaquiline, was, in 2012, the first drug in 40 years to receive US Food and Drug Administration approval for use in the treatment of tuberculosis. However, over these past 40 years, about three-quarters of all approved antibacterial drugs have been the result of semisynthetic efforts from natural-product starting points 3 . In fact, the biggest advance in tuberculosis chemotherapy so far was unquestionably the addition of rifampicin to multidrug cocktails in the 1970s. Before the introduction of rifampicin, 18-24 months of therapy with a combination of two or three different agents was required to achieve a sterile cure of tuberculosis. But, following landmark clinical trials in Africa by the British Medical Research Council, the standard therapy for tuberculosis
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Drug discovery goes au naturel
In a study that showcases the potential of semisynthetic drug design, structural modification of an existing antibiotic with little activity against Mycobacterium tuberculosis has generated a new class of effective antitubercular lead. T he research field of optical manipulation, in which microscopic particles are confined and moved about by laser light, bears more than a passing resemblance to that staple of science-fiction movies, the tractor beam. Although it may be possible to push and pull a red blood cell, say, using a laser beam, it is rather a different matter to try the same trick with billions of particles and then to make a mirror out of them. With the aim of producing ultralow-weight space-based mirrors, that is exactly what Grzegorczyk and colleagues propose, as they write in Physical Review Letters
The idea that a space mirror could be held in place using a laser beam dates back to the 1970s, when the astronomer Antoine Labeyrie proposed 2 a system in which a thin mirror called a pellicle, 10-100 metres in diameter, was trapped in the node of a standing wave formed by two counter-propagating laser beams; the node of a standing wave is the point at which the wave's amplitude is at its minimum. Furthermore, the curvature needed to enable the mirror to produce an image from incoming light could be generated naturally by the properties of the light holding the mirror in place. Two advantages of such a system are weight -large tele scopes could be made that are micrometres thick and weigh much less than 1 kilogram -and, depending on how the pellicle is formed, the fact that they could be tightly packed, reducing the volume required to deliver them into space. But how could such a mirror be created? A step towards the practical implementation of this optical device is at the heart of Grzegorczyk and colleagues' work.
The research makes use of a technique called optical binding, in which microscopic particles illuminated by laser light scatter some of the light in a transverse direction to that of the illumination. The scattered light from all the particles helps to bind them together. In the experimental part of their study, Grzegorczyk et al. create an optically bound structure of around 150 spherical polystyrene particles, each with a diameter of 3 micrometres (Fig. 1) . In contrast to Labeyrie's original proposal, this mirror is confined using only one laser beam, and is held in place by the laser pushing it against the wall of the experimental chamber. Also, unlike the situation in a practical implementation, the mirror is trapped in water, and the authors admit that there is a challenge in even this rudimentary experiment of trapping the mirror stably away from the chamber wall using a dual-beam system.
The major novelty in the latest work is the ability to use the structure as a mirror; an optically bound particle structure has already been created 3 . The imaging obtained by Grzegorczyk et al. is fairly crude, showing the number 8 on a transparent ruler reflecting from the mirror surface. The work does not demonstrate the curved mirror surface that would probably be needed for a space telescope, and it is clear that the imaging quality is a long way short of that normally expected in a high-end optical instrument.
But Grzegorczyk et al. examine the imaging ability of curved mirrors made from large numbers of particles using a numerical model, and find that focusing of incoming light should be possible. More importantly, the model also analyses how a more practical mirror design might operate. Such a mirror might be tens of metres in diameter, and require billions of particles. Although the total weight of such a structure is not an obstacle, its assembly would be. Optically bound matter becomes more unstable as the arrays of particles grow bigger, because they will contain larger numbers of structural defects known as dislocations.
Binding the particles together has the advantage that the mirror can 'self-heal' after being hit by a bit of space debris, but in the current design the binding does not scale well with particle number. This could be overcome by splitting the mirror into chunks, and the authors' modelling suggests that doing so infections became combinations of four drugs, including rifampicin, for a mere six months 4 . The starting point for rifampicin development was a complex mixture of metabolites from the bacterium Nocardia mediterranei, isolated by the Italian pharmaceutical company Lepetit in 1957. It took 8 years for this company (partnering with Ciba-Geigy, based in Switzerland) to understand the various rifampicin-related metabolites and their chemistry sufficiently to allow the development of an orally available analogue, which became the basis of these new short-course chemotherapy regimens 5 . The molecule described by Lee et al. is not the 'next rifampicin' , but there are two exciting features of the authors' paper that should encourage more effort in the semisynthetic modification of natural products for tuberculosis drug discovery. First, the authors took full advantage of recent advances in crystallography to guide their strategy for modifying the natural product. This allowed them to focus on a limited set of chemical modifications rather than the inefficient empirical approaches used in the past (for example, several hundred rifampicin analogues had to be explored before it even became clear which positions could be modified without completely losing biological activity). Second, they used our expanding understanding of the role of drug efflux in tuberculosis 6 to assess the efficacy of the modified compounds. The proof-of-concept achieved in this study will nudge the pendulum of interest back towards natural products as viable starting points for tuberculosis drug developers. ■ 
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